Share：
Share this content in WeChat
X
[Chinese][PDF]87771
• Original Article •
The change of association between nephrogenic systemic fibrosis and gadolinium-based contrast agents: an updated meta-analysis applying Hill’s criteria
ZHANG Bin  LIANG Long  CHEN Wen-bo  LI Xin-yun  ZHENG Jun-hui  LIANG Chang-hong  ZHANG Shui-xing 

DOI:10.3969/j.issn.1674-8034.2015.04.012.


[Abstract] Objective: To examine whether a causal link exists between gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) and if the link changes over time.Materials and Methods: Studies for analysis were identified by searching the PubMed, the Wiley Online Library, and the Cochrane Central Register of Controlled Trials up to December 18, 2014. Pooled odds ratios (OR) with 95% confidence intervals (CI) was calculated by using the fixed-effects model. Statistical heterogeneity was assessed by Cochrane’s Q test and I2 statistics. Publication bias was evaluated using peters test, funnel plots and fail-safe N. Quality assessment of included studies using Newcastle-Ottawa Scale (NOS). Influence analysis and cumulative meta-analysis were also conducted in this study. All statistical analyses were performed by R software (R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org, 2014). Hill’s criteria was used to evaluate evidence in support of a potential causal link between GBCAs and NSF.Results: A total of 14 studies including 6398 patients met the inclusion criteria, but 3 was excluded since they reported no NSF events. Meta-analysis of controlled trials indicated the GBCAs exposure may significantly increase the risk of NSF (OR=16. 50, 95%CI: 7.46-36.53, P<0.01) and gadodiamide exposure may also increase the risk of NSF (OR=20.04, 95%CI: 3.72-107.78, P<0.01). No heterogeneity (P=0. 819, I2=0%; P=0. 873, I2=0%, respectively) was observed across studies. Hill’s criteria suggested a potential causal link between GBCAs and NSF. In addition, the cumulative analysis demonstrated that the pooled ORs for GBCAs and NSF decreased post-2007 compared to pre-2007 (OR=26.71; 95%CI: 10.27-69.44).Conclusions: Although this meta-analysis suggests a strong association and potentially causal relation between GBCAs exposure and the incidence of NSF in patients with renal insufficiency, the relation decreased after 2007. More studies are warranted to examine the potential association between GBCAs other than gadodiamide and NSF.
[Keywords] Nephrogenic systemic fibrosis；Renal insufficiency；Gadolinium；Meta-analysis；Magnetic resonance imaging

ZHANG Bin Graduate College, Southern Medical University, Guangzhou 510515, China; Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

LIANG Long Graduate College, Southern Medical University, Guangzhou 510515, China; Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

CHEN Wen-bo Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

LI Xin-yun Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

ZHENG Jun-hui Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

LIANG Chang-hong Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

ZHANG Shui-xing* Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510080, China

*Correspondence to: Zhang SX, E-mail: shui7515@hotmail.com

Conflicts of interest   None.

Received  2015-01-11
Accepted  2015-02-11
DOI: 10.3969/j.issn.1674-8034.2015.04.012
DOI:10.3969/j.issn.1674-8034.2015.04.012.

[1]
Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo, 2014, 186(7): 661-669.
[2]
Elmholdt TR, Olesen AB, Jorgensen B, et al. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One, 2013, 8(12): e82037.
[3]
Gupta A, Shamseddin MK, Khaira A. Pathomechanisms of nephrogenic systemic fibrosis: new insights. Clin Exp Dermatol, 2011, 36(7): 763-768.
[4]
Kitajima K, Maeda T, Watanabe S, et al. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol, 2012, 19(9): 806-811.
[5]
Swaminathan S, Bose C, Shah S V, et al. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol, 2013, 183(3): 796-807.
[6]
Heinz-Peer G, Neruda A, Watschinger B, et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol, 2010, 76(1): 129-134.
[7]
Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol, 2008, 190(4): 1060-1068.
[8]
Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum, 2007, 56(10): 3433-3441.
[9]
Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant, 2007, 22(11): 3179-3185.
[10]
Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology, 2007, 245(1): 168-175.
[11]
Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol, 2007, 2(2): 264-267.
[12]
Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol, 2007, 188(2): 586-592.
[13]
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol, 2006, 17(9): 2359-2362.
[14]
Centers for Disease Control and Prevention(CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St.Louis,Missouri,2002-2006. MMWR Morb Mortal Wkly Rep, 2007, 56(7): 137-141.
[15]
Elmholdt TR, Pedersen M, Jorgensen B, et al. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency:a case-control study from Denmark. Br J Dermatol, 2011, 165(4): 828-836.
[16]
Amet S, Launay-Vacher V, Clement O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents:the Prospective Fibrose Nephrogenique Systemique study. Invest Radiol, 2014, 49(2): 109-115.
[17]
Becker S, Walter S, Witzke O, et al. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. Nephron Clin Pract, 2012, 121(1-2): c91-c94.
[18]
Deray G, Rouviere O, Bacigalupo L, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol, 2013, 23(5): 1250-1259.
[19]
Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol, 2010, 73(2): 357-359.
[20]
Wells GA, Shea B, O' Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. DOI: : www.ohri.ca/programs/clinical_epidemiology/oxford.asp. DOI: .
[21]
Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 2011, 343: d4002.
[22]
Hill AB. The Environment and Disease: Association or Causation?. Proc R Soc Med, 1965, 58: 295-300.
[23]
Kitajima K, Maeda T, Watanabe S, et al. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol, 2012, 19(9): 806-811.
[24]
Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology, 2012, 265(1): 248-253.
[25]
Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media:updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol, 2013, 23(2): 307-318.
[26]
Daftari BL, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol, 2014, 69(7): 661-668.
[27]
Kim KH, Fonda JR, Lawler EV, et al. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008. Am J Kidney Dis, 2010, 56(3): 458-467.
[28]
Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am, 2008, 16(4): 551-560.
[29]
Juluru K, Vogel-Claussen J, Macura KJ, et al. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics, 2009, 29(1): 9-22.
[30]
Cowper SE. Gadolinium - is it to blame?. J Cutan Pathol, 2008, 35(5): 520-522.
[31]
Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. J Magn Reson Imaging, 2013, 37(3): 501-530.
[32]
Chrysochou C, Power A, Shurrab A E, et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol, 2010, 5(3): 484-489.
[33]
Grebe SO, Borrmann M, Altenburg A, et al. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol, 2008, 12(5): 403-406.
[34]
Cowper SE. The international center for nephrogenic fibrosing dermopathy research(ICNFDR): official site of the nephrogenic fibrosing dermopathy (NFD/NSF). Registry, 2007: 1-6.
[35]
de Campos RO, Heredia V, Ramalho M, et al. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis:preliminary observations. AJR Am J Roentgenol, 2011, 196(3): 545-552.
[36]
曾庆斌，郭茜旎，罗晴，等．锰对比剂在MRI中的应用．磁共振成像, 2014, 5(4): 315-320.
[37]
安靖，孙治国，张琼．无对比剂增强的磁共振血管成像技术．磁共振成像, 2011, 2(1): 65-68.

PREV Research of magnetic resonance perfusion weighted imaging in the characteristics of cervical cancer
NEXT Malignant mixed genetical cell tumors in basal ganglia: a case report
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn